Equifax Inc. (NYSE:EFX) Shares Bought by Raymond James Trust N.A.

Raymond James Trust N.A. lifted its position in shares of Equifax Inc. (NYSE:EFX) by 1.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 21,537 shares of the credit services provider’s stock after purchasing an additional 213 shares during the quarter. Raymond James Trust N.A.’s holdings in Equifax were worth $6,329,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. International Assets Investment Management LLC raised its stake in Equifax by 76,913.8% in the 3rd quarter. International Assets Investment Management LLC now owns 960,362 shares of the credit services provider’s stock valued at $282,212,000 after purchasing an additional 959,115 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in Equifax by 72.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,514,093 shares of the credit services provider’s stock worth $405,051,000 after buying an additional 633,887 shares during the period. Massachusetts Financial Services Co. MA lifted its holdings in Equifax by 4.9% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 4,276,798 shares of the credit services provider’s stock worth $1,036,952,000 after buying an additional 200,665 shares in the last quarter. Ceredex Value Advisors LLC boosted its position in Equifax by 127.1% in the 2nd quarter. Ceredex Value Advisors LLC now owns 350,356 shares of the credit services provider’s stock valued at $84,947,000 after buying an additional 196,106 shares during the period. Finally, American Century Companies Inc. grew its stake in shares of Equifax by 27.3% in the second quarter. American Century Companies Inc. now owns 606,969 shares of the credit services provider’s stock worth $147,166,000 after acquiring an additional 130,249 shares in the last quarter. 96.20% of the stock is owned by hedge funds and other institutional investors.

Equifax Price Performance

EFX opened at $253.58 on Friday. The company has a debt-to-equity ratio of 0.96, a quick ratio of 0.88 and a current ratio of 0.88. Equifax Inc. has a 1-year low of $208.67 and a 1-year high of $309.63. The company has a 50-day moving average of $277.59 and a 200-day moving average of $267.73. The company has a market capitalization of $31.43 billion, a P/E ratio of 56.35, a PEG ratio of 2.31 and a beta of 1.59.

Equifax (NYSE:EFX) last announced its quarterly earnings results on Wednesday, October 16th. The credit services provider reported $1.85 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.84 by $0.01. Equifax had a return on equity of 18.56% and a net margin of 10.07%. The business had revenue of $1.44 billion for the quarter, compared to the consensus estimate of $1.44 billion. During the same quarter last year, the business posted $1.76 EPS. The business’s revenue was up 9.3% on a year-over-year basis. Equities analysts expect that Equifax Inc. will post 7.28 EPS for the current fiscal year.

Equifax Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 13th. Stockholders of record on Friday, November 22nd will be given a dividend of $0.39 per share. The ex-dividend date is Friday, November 22nd. This represents a $1.56 annualized dividend and a dividend yield of 0.62%. Equifax’s dividend payout ratio (DPR) is 34.67%.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on EFX shares. Wells Fargo & Company reaffirmed a “buy” rating on shares of Equifax in a research report on Friday, October 18th. Barclays upped their price objective on Equifax from $300.00 to $380.00 and gave the stock an “overweight” rating in a research report on Friday, September 13th. The Goldman Sachs Group raised their target price on Equifax from $277.00 to $307.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 20th. UBS Group started coverage on shares of Equifax in a research note on Tuesday, October 1st. They issued a “buy” rating and a $360.00 price target on the stock. Finally, Needham & Company LLC restated a “buy” rating and set a $350.00 price objective on shares of Equifax in a research report on Monday, October 28th. Four research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $306.74.

Insider Transactions at Equifax

In related news, EVP John J. Kelley III sold 1,000 shares of the firm’s stock in a transaction that occurred on Friday, October 25th. The shares were sold at an average price of $272.92, for a total transaction of $272,920.00. Following the transaction, the executive vice president now owns 11,269 shares of the company’s stock, valued at approximately $3,075,535.48. This trade represents a 8.15 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Mark W. Begor sold 58,304 shares of the stock in a transaction that occurred on Friday, October 25th. The shares were sold at an average price of $270.49, for a total value of $15,770,648.96. Following the transaction, the chief executive officer now owns 109,183 shares in the company, valued at approximately $29,532,909.67. This trade represents a 34.81 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.57% of the company’s stock.

About Equifax

Equifax Inc operates as a data, analytics, and technology company. The company operates through three segments: Workforce Solutions, U.S. Information Solutions (USIS), and International. The Workforce Solutions segment offers services that enables customers to verify income, employment, educational history, criminal justice data, healthcare professional licensure, and sanctions of people in the United States; and employer customers with services that assist them in complying with and automating payroll-related and human resource management processes throughout the entire cycle of the employment relationship.